According to filings with the U.S. Securities and Exchange Commission, Imio Technologies is raising up to $12 Million in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Imio Technologies
Imio Technologies, operating as IMIO, is a biotechnology company focused on regenerative agriculture, developing natural microbial products that help farmers improve soil health, crop performance, and profitability while reducing dependence on chemical inputs. The companys biological solutions use carefully formulated microbes to break down crop residue into bioavailable nutrients and deliver consistent NPK value, providing chemical-like reliability with the environmental and sustainability benefits of biologicals. IMIO emphasizes robust performance across a wide range of crops, soils, and climates, under real-world farm conditions rather than perfect lab scenarios, positioning its products as practical, high-ROI tools for working farms. Its offerings, such as residue management and plant growth products, are designed to make farming more sustainable both environmentally and economically, reflecting a mission to give growers a viable alternative to traditional chemical regimens. Backed by years of research and on-farm use, IMIO presents itself as a pioneer in next-generation biologicals and biomanufacturing for agriculture, aiming to shape the future of farming by aligning modern science with nature.

To learn more, visit https://www.imio.co/
LinkedIn: https://www.linkedin.com/company/imio-co

Contact:
Charles Smith, Chief Executive Officer

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.